Memento

Memento is advancing novel antibody therapies for retinal diseases. Its lead program is in development for neovascular AMD and diabetic macular edema.

Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series A
Initial Investment Year
2026
Memento logo